NCT04682548

Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients

Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients With and Without Ocrelizumab Treatment, and Comparing Immune Responses to COVID-19 in MS Patients on Ocrelizumab and Healthy Controls

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 920 (actual)
• Sponsor: NYU Langone Health · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This non-interventional, biospecimen collection study is designed to help us better understand whether MS patients have impaired immune defenses to COVID-19 infection. The potential influence of immune modulating medications for MS will be considered through these exploratory studies. This study is also designed to provide context for interpretation of anti-SARS CoV2 serologies in MS patients during convalescence from COVID-19 infection.

Conditions

• Multiple Sclerosis
• Covid19

Timeline

• Start date: 2021-01-05
• Primary completion: 2022-09-15
• Completion: 2022-09-15
• First posted: 2020-12-23
• Last updated: 2022-11-03

Locations

1 site across 1 country: United States